Skip to main content
OpenTrials
Completed

NCT Number: NCT03395418

Evaluation of the Right Use of Inhaled Therapeutics

Asthma and COPD have a significant impact on public health, affecting about 8 million people in France and generating health care costs of 5.5 billion euros, almost 50% of which are dedicated to long-term treatments are essentially inhaled therapies.

The good control of the disease depends on the patient's compliance, but also on the proper use of the devices used for the administration of inhaled drugs under penalty of the degradation of the control of the disease with major medical and medico-economic consequences.

Thus, education of these patients in the use of devices must be an integral part of medical care. It comes up against the complexity of the therapeutic arsenal on the one hand and on the other hand with its time-consuming nature: this makes it incompatible with a realization in consultation.

The "ARGOS" process is a telemonitoring project for the support of therapeutic education, consisting in setting up a concrete and real-time relay between prescribers and patients for the education of inhaled therapeutics.

Its objective is to provide the answer to what is currently an "unmet need" in the management of asthma and COPD, with the prospect of a positive impact on the observance of these treatments and by consequently their clinical and economic efficiency.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD Asthma Asthma Bronchial Diseases Chronic Disease Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

ANTADIR

Paris, 75006, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient followed in Pneumology for asthma or COPD with a prescription for long-term inhaled therapies AND a home health provider (who monitors either home oxygen and / or respiratory equipment)
  • The patient must have a means of telephone communication in order to be able to be contacted by a provider, an H2AD permanence or a doctor
  • Patient having given his agreement after having been informed in writing of the purpose and the data collected during this study
  • Age ≥ 18 years
  • Beneficiary of a social security scheme

Exclusion criteria

  • Refusal of the patient
  • Patient not understanding French
  • Absence of home health provider
  • Absence of means of telephone communication

Treatment and study plan

Primary outcomes

  1. Percentage of exploitable films

    Time frame: Day 1 to day 7

    Ratio between the number of exploitable films and the number of films arriving at the telemedicine platform.

Sponsors and collaborators

Lead sponsor

Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche

Other

Registry information

Official study title

Evaluation of the Right Use of Inhaled Therapeutics Prescribed in Asthma and COPD in Adults

Acronym: ARGOS

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jan 10, 2018
Registry last updated
Mar 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.